NCT00533923: Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders |
|
|
| Completed | 2 | 25 | US | Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF, Cytoxan;, Fludara;, Leukine; | Beth Israel Deaconess Medical Center, Bayer | AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder | 01/07 | 01/07 | | |
